AKTS (Aktis Oncology) Total Operating Expense: $45.18 Mil (TTM As of Mar. 2026)


AKTS Aktis Oncology Inc AKTS
9 GF Score
Price $28.14
! 3 Warning Signs
View Full Analysis

What is Aktis Oncology Total Operating Expense?

Aktis Oncology AKTS -11.40% 9 Total Operating Expense is $45.18 Mil as of Mar. 2026. GuruFocus rates AKTS with a GF Score™ of 9/100. The stock has 3 warning signs investors should review.

Aktis Oncology's Total Operating Expense for the three months ended in Mar. 2026 was $25.93 Mil. Aktis Oncology's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $45.18 Mil.

Aktis Oncology Total Operating Expense Related Terms

Aktis Oncology Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Aktis Oncology's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aktis Oncology Total Operating Expense Chart

Aktis Oncology Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Operating Expense
19.76 34.79 53.54 81.18

Aktis Oncology Quarterly Data
Dec22 Dec23 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial 16.57 19.59 0.00 19.25 25.93
AKTS
9GF Score
Aktis Oncology Inc AKTS
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aktis Oncology Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $45.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $45.18 Mil mean?
Aktis Oncology (AKTS) has a Total Operating Expense of $45.18 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Aktis Oncology and its competitors.
Is Aktis Oncology's Total Operating Expense too high?
Aktis Oncology's current Total Operating Expense is $45.18 Mil. Overall, Aktis Oncology has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Aktis Oncology's Total Operating Expense compare to ZBIO and MLTX?
Aktis Oncology's Total Operating Expense of $45.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Aktis Oncology and its competitors. Aktis Oncology's current Total Operating Expense is $45.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aktis Oncology stock overvalued right now?
Aktis Oncology (AKTS) has a current Total Operating Expense of $45.18 Mil. The current Total Operating Expense is $45.18 Mil. Aktis Oncology's overall GF Score™ is 9/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Aktis Oncology (AKTS), the current Total Operating Expense is $45.18 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aktis Oncology Business Description

Address 17 Drydock Avenue, Suite 17-401, Boston, MA, USA, 02210
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
9GF Score

Get the complete analysis for AKTS

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.14
Price